Posted by Michael Wonder on 05 Feb 2025
Adicet Bio receives FDA fast track designation for ADI-001 for the treatment of refractory systemic lupus erythematosus with extra-renal involvement
5 February 2025 - Adicet Bio today announced the US FDA has granted fast track designation to ADI-001 for the potential treatment of adult patients with refractory systemic lupus erythematosus with extra-renal involvement.
ADI-001 is an investigational allogeneic gamma delta chimeric antigen receptor T cell therapy targeting CD20 for the treatment of auto-immune diseases.
